Department of Immune Modulation
Alexander Steinkasserer, studied biology at the University of Innsbruck. From 1986 until 1989 he worked as a Postdoctoral Fellow at the Institute for Immunology at the Ludwig-Maximilians-Universität München (LMU) and subsequently as a Research Fellow at the University of Oxford (1989-93). From 1993 until 1996 he was laboratory head at the Novartis Research Institute in Vienna and from 1996 until 1997 head of division at the Baxter AG Vienna. From 1997 until 1998 he served as head of division at the Immunological Day Clinic Vienna. Since 1998 he is appointed professor at the Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and head of the department of “Immune Modulation”, at the University Hospital Erlangen. His research interests are focused on the human immune system, with the long term aim to develop new therapeutic strategies for patients suffering from cancer, infections or autoimmune disorders. He published over 150 scientific articles in peer reviewed international journals. In addition, several international patents have been granted to Prof. Steinkasserer, which represents the intellectual property to successfully translate basic research into applicable and economically sustainable therapy approaches. Furthermore, he very successfully acquired third party money, amongst others, from the “German Science Foundation”.
Infection of dendritic cells with herpes simplex virus type 1 induces rapid degradation of CYTIP, thereby modulating adhesion and migration.
Blood Jul, 2011 | Pubmed ID: 21562043
Leukoreduction system chambers are an efficient, valid, and economic source of functional monocyte-derived dendritic cells and lymphocytes.
Immunobiology Nov, 2013 | Pubmed ID: 23932569
Electroporation of siRNA into mouse bone marrow-derived macrophages and dendritic cells.
Methods in molecular biology (Clifton, N.J.) , 2014 | Pubmed ID: 24510816
CD83 and GRASP55 interact in human dendritic cells.
Biochemical and biophysical research communications Mar, 2015 | Pubmed ID: 25701785
CD83 Modulates B Cell Activation and Germinal Center Responses.
Journal of immunology (Baltimore, Md. : 1950) 05, 2016 | Pubmed ID: 26983787
Transcriptional Targeting of Mature Dendritic Cells with Adenoviral Vectors via a Modular Promoter System for Antigen Expression and Functional Manipulation.
Journal of immunology research , 2016 | Pubmed ID: 27446966
Autophagic degradation of lamins facilitates the nuclear egress of herpes simplex virus type 1.
The Journal of cell biology Feb, 2019 | Pubmed ID: 30587512
Soluble CD83 Triggers Resolution of Arthritis and Sustained Inflammation Control in IDO Dependent Manner.
Frontiers in immunology , 2019 | Pubmed ID: 31001257
Endogenous Expression of the Human CD83 Attenuates EAE Symptoms in Humanized Transgenic Mice and Increases the Activity of Regulatory T Cells.
Frontiers in immunology , 2019 | Pubmed ID: 31293592
CD83 orchestrates immunity toward self and non-self in dendritic cells.
JCI insight Oct, 2019 | Pubmed ID: 31527313
JoVEについて
Copyright © 2023 MyJoVE Corporation. All rights reserved